Zosano Pharma (NASDAQ:ZSAN) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01, Fidelity Earnings reports.

Shares of ZSAN traded down $0.13 during mid-day trading on Thursday, hitting $2.79. 125,883 shares of the company traded hands, compared to its average volume of 201,254. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.79 and a current ratio of 0.79. The business has a 50-day moving average price of $3.07. Zosano Pharma has a 1 year low of $1.85 and a 1 year high of $6.65. The company has a market cap of $52.10 million, a PE ratio of -0.75 and a beta of 2.60.

Several research analysts have recently weighed in on ZSAN shares. ValuEngine raised shares of Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised shares of Zosano Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Thursday, June 27th. Cantor Fitzgerald started coverage on shares of Zosano Pharma in a report on Monday, April 22nd. They set an “overweight” rating and a $3.66 price objective for the company. Finally, Maxim Group started coverage on shares of Zosano Pharma in a report on Wednesday, April 17th. They set a “buy” rating and a $8.00 price objective for the company. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $8.54.

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

See Also: What is the Bid-Ask Spread?

Earnings History for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.